SynthesisOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025
A cost-saving analysis of pharmacologic management in osteoporotic fracture prevention among postmenopausal women.
Synthesis in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Report of the FDA's expert panel on hormone therapy.Menopause (New York, N.Y.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacologic therapy reduces osteoporotic fractures and generates substantial cost savings. A meta-analysis of 30 RCTs showed bisphosphonates, HRT, and biologics lower fracture risk by 31%, 27%, and 40%, respectively. Cost analysis revealed net savings of up to $12.8 billion annually and up to $118 billion over the next 10 years. PURPOSE: Osteoporotic fractures are a significant concern among postmenopausal women, leading to substantial healthcare costs. This study aims to evaluate the cost savings associated with pharmacologic management in preventing osteoporotic fractures among postmenopausal women.
methodsA systematic review and meta-analysis were conducted to evaluate pharmacologic interventions for osteoporotic fracture prevention in postmenopausal women and identified studies comparing HRT, bisphosphonates, and biologics to placebo. A random-effects model was used to pool data and assess fracture reduction. Cost analysis utilized Medicare data, including cost and expenditures. Net savings were calculated by subtracting drug costs from gross savings, with a 10-year projection estimating long-term economic impact.
resultsA meta-analysis of 30 randomized controlled trials (86,411 patients) showed a significant reduction in fracture risk with pharmacologic therapy (RR = 0.70, p < 0.001). HRT reduced fracture risk by 27%, bisphosphonates by 31%, and biologics by 40%. Cost analysis showed annual net savings of $3.35B for bisphosphonates, $3.01B for HRT, and $1.33B for biologics at $8600 per fracture. Over 10 years, HRT could reduce cumulative costs by $118B.
conclusionsPharmacologic therapies, particularly bisphosphonates and hormone therapy, effectively reduce fracture incidence and generate substantial cost savings in high-risk postmenopausal women. Enhancing accessibility, affordability, and adherence through system-wide initiatives can mitigate osteoporosis's economic burden. Future research should optimize treatment strategies and assess emerging therapies for cost-effectiveness and long-term sustainability.
Indexed as
Identifiers
40748369What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.